Cargando…

Altered expression of microRNA in the airway wall in chronic asthma: miR-126 as a potential therapeutic target

BACKGROUND: The role of microRNAs (miRNAs) in regulating gene expression is currently an area of intense interest. Relatively little is known, however, about the role of miRNAs in inflammatory and immunologically-driven disorders. In a mouse model, we have previously shown that miRNAs are potentiall...

Descripción completa

Detalles Bibliográficos
Autores principales: Collison, Adam, Herbert, Cristan, Siegle, Jessica S, Mattes, Joerg, Foster, Paul S, Kumar, Rakesh K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116478/
https://www.ncbi.nlm.nih.gov/pubmed/21605405
http://dx.doi.org/10.1186/1471-2466-11-29
_version_ 1782206250126147584
author Collison, Adam
Herbert, Cristan
Siegle, Jessica S
Mattes, Joerg
Foster, Paul S
Kumar, Rakesh K
author_facet Collison, Adam
Herbert, Cristan
Siegle, Jessica S
Mattes, Joerg
Foster, Paul S
Kumar, Rakesh K
author_sort Collison, Adam
collection PubMed
description BACKGROUND: The role of microRNAs (miRNAs) in regulating gene expression is currently an area of intense interest. Relatively little is known, however, about the role of miRNAs in inflammatory and immunologically-driven disorders. In a mouse model, we have previously shown that miRNAs are potentially important therapeutic targets in allergic asthma, because inhibition of miR-126, one of a small subset of miRNAs upregulated in the airway wall, effectively suppressed Th2-driven airway inflammation and other features of asthma. In the present study, we extended investigation of the therapeutic potential of miRNA inhibition to our well-established model of chronic asthma. METHODS: Female BALB/c mice were systemically sensitised with ovalbumin (OVA) and chronically challenged with low mass concentrations of aerosolised OVA for up to 6 weeks. Airway tissue was obtained by blunt dissection and RNA was isolated for miRNA profiling. On the basis of the results obtained, animals were subsequently treated with either an antagomir to miR-126 (ant-miR-126) or a scrambled control antagomir once weekly during the 6 weeks of chronic challenge, and the effects on airway inflammation and remodelling were assessed using established morphometric techniques. RESULTS: Compared to naïve mice, there was selective upregulation of a modest number of miRNAs, notably miR-126, in the airway wall tissue of chronically challenged animals. The relative increase was maximal after 2 weeks of inhalational challenge and subsequently declined to baseline levels. Compared to treatment with the scrambled control, ant-miR-126 significantly reduced recruitment of intraepithelial eosinophils, but had no effect on the chronic inflammatory response, or on changes of airway remodelling. CONCLUSIONS: In this model of chronic asthma, there was an initial increase in expression of a small number of miRNAs in the airway wall, notably miR-126. However, this later declined to baseline levels, suggesting that sustained changes in miRNA may not be essential for perpetuation of chronic asthma. Moreover, inhibition of miR-126 by administration of an antagomir suppressed eosinophil recruitment into the airways but had no effect on chronic inflammation in the airway wall, or on changes of remodelling, suggesting that multiple miRNAs are likely to regulate the development of these lesions.
format Online
Article
Text
id pubmed-3116478
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31164782011-06-17 Altered expression of microRNA in the airway wall in chronic asthma: miR-126 as a potential therapeutic target Collison, Adam Herbert, Cristan Siegle, Jessica S Mattes, Joerg Foster, Paul S Kumar, Rakesh K BMC Pulm Med Research Article BACKGROUND: The role of microRNAs (miRNAs) in regulating gene expression is currently an area of intense interest. Relatively little is known, however, about the role of miRNAs in inflammatory and immunologically-driven disorders. In a mouse model, we have previously shown that miRNAs are potentially important therapeutic targets in allergic asthma, because inhibition of miR-126, one of a small subset of miRNAs upregulated in the airway wall, effectively suppressed Th2-driven airway inflammation and other features of asthma. In the present study, we extended investigation of the therapeutic potential of miRNA inhibition to our well-established model of chronic asthma. METHODS: Female BALB/c mice were systemically sensitised with ovalbumin (OVA) and chronically challenged with low mass concentrations of aerosolised OVA for up to 6 weeks. Airway tissue was obtained by blunt dissection and RNA was isolated for miRNA profiling. On the basis of the results obtained, animals were subsequently treated with either an antagomir to miR-126 (ant-miR-126) or a scrambled control antagomir once weekly during the 6 weeks of chronic challenge, and the effects on airway inflammation and remodelling were assessed using established morphometric techniques. RESULTS: Compared to naïve mice, there was selective upregulation of a modest number of miRNAs, notably miR-126, in the airway wall tissue of chronically challenged animals. The relative increase was maximal after 2 weeks of inhalational challenge and subsequently declined to baseline levels. Compared to treatment with the scrambled control, ant-miR-126 significantly reduced recruitment of intraepithelial eosinophils, but had no effect on the chronic inflammatory response, or on changes of airway remodelling. CONCLUSIONS: In this model of chronic asthma, there was an initial increase in expression of a small number of miRNAs in the airway wall, notably miR-126. However, this later declined to baseline levels, suggesting that sustained changes in miRNA may not be essential for perpetuation of chronic asthma. Moreover, inhibition of miR-126 by administration of an antagomir suppressed eosinophil recruitment into the airways but had no effect on chronic inflammation in the airway wall, or on changes of remodelling, suggesting that multiple miRNAs are likely to regulate the development of these lesions. BioMed Central 2011-05-23 /pmc/articles/PMC3116478/ /pubmed/21605405 http://dx.doi.org/10.1186/1471-2466-11-29 Text en Copyright ©2011 Collison et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Collison, Adam
Herbert, Cristan
Siegle, Jessica S
Mattes, Joerg
Foster, Paul S
Kumar, Rakesh K
Altered expression of microRNA in the airway wall in chronic asthma: miR-126 as a potential therapeutic target
title Altered expression of microRNA in the airway wall in chronic asthma: miR-126 as a potential therapeutic target
title_full Altered expression of microRNA in the airway wall in chronic asthma: miR-126 as a potential therapeutic target
title_fullStr Altered expression of microRNA in the airway wall in chronic asthma: miR-126 as a potential therapeutic target
title_full_unstemmed Altered expression of microRNA in the airway wall in chronic asthma: miR-126 as a potential therapeutic target
title_short Altered expression of microRNA in the airway wall in chronic asthma: miR-126 as a potential therapeutic target
title_sort altered expression of microrna in the airway wall in chronic asthma: mir-126 as a potential therapeutic target
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116478/
https://www.ncbi.nlm.nih.gov/pubmed/21605405
http://dx.doi.org/10.1186/1471-2466-11-29
work_keys_str_mv AT collisonadam alteredexpressionofmicrornaintheairwaywallinchronicasthmamir126asapotentialtherapeutictarget
AT herbertcristan alteredexpressionofmicrornaintheairwaywallinchronicasthmamir126asapotentialtherapeutictarget
AT sieglejessicas alteredexpressionofmicrornaintheairwaywallinchronicasthmamir126asapotentialtherapeutictarget
AT mattesjoerg alteredexpressionofmicrornaintheairwaywallinchronicasthmamir126asapotentialtherapeutictarget
AT fosterpauls alteredexpressionofmicrornaintheairwaywallinchronicasthmamir126asapotentialtherapeutictarget
AT kumarrakeshk alteredexpressionofmicrornaintheairwaywallinchronicasthmamir126asapotentialtherapeutictarget